Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care Diagnostics and Biosensors 2021

Point-of-Care Diagnostics and Biosensors 2021 Agenda



Co-Located Conference Agendas

Extracellular Vesicles (EVs): Technologies & Biological Investigations | Lab-on-a-Chip and Microfluidics 2021 | Organoids & Organs-on-Chips 2021 | Point-of-Care Diagnostics and Biosensors 2021 | 

Print Agenda

Monday, 13 December 2021

13:00

Conference Registration and Materials Pick-Up


Session Title: Conference Plenary Session


Venue: Marriott Coronado Island Ballrooms C & D

14:00

Leanna LevineConference Chair

Welcome and Introduction by Conference Co-Chair -- Lab-on-a-Chip and Microfluidics -- Inputs and Outputs in Product Engineering
Leanna Levine, Founder & CEO, ALine, Inc., United States of America

A unique aspect to point-of-care product development is to determine if the biological or chemical test will perform in a microfluidic system often before the rest of the product concept is thoroughly fleshed out. This means the programmatic priorities are focused on translational research before developing design inputs for a regulated product with an instrument. ALine’s new partnership with Nectar Product Development will enable us to support not just the assay implementation, but also create the entire product development roadmap, including the path to regulatory approval.

14:10

Claudia GärtnerConference Chair

Welcome introduction by Conference Co-Chair Lab-on-a-Chip, Microfluidics & Associated Fields – Current Status: The Two Pathways – Simple Standard Devices Versus Highly Individualized Integrated Devices
Claudia Gärtner, CEO, microfluidic ChipShop GmbH, Germany

This presentation will pinpoint two interesting completely different ways for the use and the style of Lab-on-a-Chip devices: namely the simpler standard devices and the highly specific multifunctional integrated lab-on-a-chip devices. Point-of-care diagnostic has been one of the most prominent fields for lab-on-a-chip devices in particular since the last years during the pandemic. These devices are rather specific and highly individualized from the different companies commercializing them. A different pathway are easier standard devices, less application specific that are provided off-the-shelf from various companies and are frequently used with existing non-specific-lab-on-a-chip laboratory equipment. This “Lab-on-a-Chip-Catalogue” of an ever-growing number of different devices from various suppliers round the globe is worth to be highlighted and the use of existing standards and the creation of new ones should be shown as “the second way” for microfluidics.

14:20

Lucia LanguinoConference Chair

Welcome and Introduction by Conference Co-Chair -- Extracellular Vesicles and Cellular Communication
Lucia Languino, Professor of Cancer Biology, Thomas Jefferson University, United States of America

14:30

Nancy AllbrittonKeynote Presentation

Development of Novel Intestine-on-Chip Models
Nancy Allbritton, Frank and Julie Jungers Dean of the College of Engineering and Professor of Bioengineering, University of Washington in Seattle, United States of America

Organ-on-chips are miniaturized devices that arrange living cells to simulate functional subunits of tissues and organs. These microdevices provide exquisite control of the biochemical and biophysical microenvironment for the investigation of organ-level physiology and disease. 2D and 3D models displaying a polarized human colonic epithelium were developed to recapitulate gastrointestinal physiology. The 2D crypt mimic displays a spatially patterned monolayer of epithelium displaying a stem-cell niche and differentiated cell zone with cells migration between the two regions. This planar 2D format enables efficient image cytometry for high-throughput screening applications as well physiologic measurements difficult to perform in a 3D format e.g., calcium signaling measurements. The 3D model builds on the 2D model by providing the full architecture of the in vivo human crypt. These models support formation of gradients of growth factors, microbial metabolites, and gases. A thick impenetrable layer of mucus with biophysical parameters similar to that of a living human can be formed for epithelial cell-microbe studies. These bioanalytical platforms are envisioned as next-generation systems for assay of microbiome-behavior, drug-delivery, and toxin-interactions with normal and diseased intestinal epithelia.

15:00

Steve SoperKeynote Presentation

Affinity Selection of Extracellular Vesicles using Plastic-based Microfluidic Devices for the Management of Different Diseases
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology, United States of America

We have been developing tools for the diagnosis of a variety of diseases. The commonality in these tools is that they consist of microfluidic devices made from plastics via injection molding. Thus, our tools can be mass produced at low-cost to facilitate bench-to-bed side transition and point-of-care testing (PoCT). We have also been generating novel assays focused on using liquid biopsy samples that are enabled using microfluidics. In this presentation, I will talk about the evolution of our fabrication efforts of plastic-based microfluidic and nanofluidic devices as well their surface modification to make the devices biocompatible for in vitro diagnostics. One tool that we have generated is a plastic device (38 × 42 mm) that consists of 1.5M pillars, which are surface decorated with affinity agents targeting certain disease-associated extracellular vesicles (EVs). The affinity agents are covalently attached to the surface of the microfluidic device using a bifunctional linker, which consists of a coumarin moiety to allow for the photolytic release of the captured EVs using a blue-light LED to minimize photodamage to the EVs’ molecular cargo. We have also developed a high-throughput nano-Coulter counter (nCC) made from a plastic via injection molding for the counting of captured EVs from clinical samples to allow their enumeration. The nCC consists of multiple pores that are ~350 nm to allow for high throughput counting with exquisite LODs (500 EVs/mL). In this presentation, I will discuss the utility of these microfluidic and nanofluidic devices in several diseases, for example, using EVs as a source of mRNAs for molecular sub-typing of breast cancer patients. EVs were affinity selected from breast-cancer patients’ plasma by searching for both epithelial and mesenchymal expressing EVs to allow for highly efficient sub-typing using the PAM50 gene panel. In an addition, the microfluidic and nanofluidic devices were integrated into a single platform (modular-based system) for PoCT to screen for early stage ovarian cancer. Affinity probes were used to target EVs specifically generated from tumor cells that signal early-stage ovarian cancer disease with the nCC used for enumerating the number of EVs captured. Finally, the modular system was used for the detection of COVID-19 at the PoC by affinity selecting SARS-CoV-2 viral particles. The integrated system could process saliva samples to search for the viral particles and count them in <20 min.

15:30

Coffee Break and Networking

16:00

Valérie TalyKeynote Presentation

From Droplet-based Microfluidics Developments to Droplet-based Digital PCR
Valérie Taly, CNRS Research Director, Group leader Translational Research and Microfluidics, University Paris Descartes, France

Droplet-based microfluidics has led to the development of highly powerful systems that represent a new paradigm in High-Throughput Screening where individual assays are compartmentalized within microdroplet microreactors. The integration of such systems for series of complex individual operations on droplets has offered a solution to the necessary miniaturization and automation of individual biological assays. By combining a decrease of assay volume and an increase of throughput, this technology goes beyond the capacities of conventional screening systems. We will show how by combining droplet-based microfluidic systems and clinical advances in molecular diagnostic we have developed an original method to perform millions of single molecule PCR in parallel to detect and quantify a minority of mutant sequences within a high quantity of non-mutated sequences in complex mixture of DNA with a sensitivity and precision that was unreachable by conventional procedures.

16:30

Daniel ChiuKeynote Presentation

High-Purity and High-Sensitivity Rare-Cell Isolation with Aliquot Sorting
Daniel Chiu, A. Bruce Montgomery Professor of Chemistry, University of Washington, United States of America

This presentation describes the high-sensitivity isolation of rare cells, including circulating tumor cells and fetal cells, using fluorescence activated aliquot sorting. Here, a blood sample is divided into nanoliter volumes or aliquots, then analyzed and sorted based on the presence or absence of a rare cell. By performing two rapid, on the millisecond timescale, back-to-back sorting, we also demonstrate isolation of rare cells with high purity. Finally, we drastically increased the number of nucleated cells sorted by first concentrating peripheral blood mononuclear cells from whole blood, which translated into an equivalent blood volume analyzed by over an order of magnitude, from 8mL to over 100mL per experiment.

17:00

Dominique PV de KleijnKeynote Presentation

Extracellular Vesicles: Liquid Biopsies and Biological Nanocarriers For Therapy
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands

17:30

John WikswoKeynote Presentation

Over-Engineering in the Life Sciences: Microfluidics and Microphysiological Systems Meet Artificial Intelligence
John Wikswo, Gordon A. Cain University Professor, A.B. Learned Professor of Living State Physics; Founding Director, Vanderbilt Institute for Integrative Biosystems, Vanderbilt University, United States of America

It is a worthwhile exercise to examine whether the addition of microfluidic pumps and valves to organ-chip systems represents either “over-engineering” or the means by which microphysiological systems can be made massively parallel. While several cited examples of over-engineering represent overly complicated or frivolous solutions to a problem, such as the $400 Juicero juice-pouch-squeezer or a $1,390 Porsche roof box rated at 200 km/hour, others are prescient and ultimately yield great value, for example the NASA Opportunity rover whose mission was planned to last 90 Mars sols (~93 Earth days) but in fact lasted 14 Earth years, and Mercedes Benz’s introduction in the 1970s of antilock braking systems and in 1980 the driver’s airbag and seat-belt tensioner. From the perspective of a biologist who uses an agar-filled Petri dish for microbial colony picking, a 1536 well plate and its associated high-throughput screening infrastructure are overkill; for big Pharma, it is a welcome tool that took 15 years to be refined and put into practical use. As we approach the 15th anniversary of Mike Shuler’s landmark 2007 patent “Devices and Methods for Pharmacokinetic-based Cell Culture System,” we realize that microfluidic tissue and organ chips have been perfused using gravity, pressurized reservoirs, external syringe or peristaltic pumps, or on-chip peristaltic pumps. Although the smallest devices abound with Quake-style pneumatic valves that also serve as pumps, very few organ-chip systems utilize valves. For over a decade, our group has been developing microfluidic pumps and valves, and we have long argued that multi-organ microphysiological systems will ultimately need automation of pumps and valves to control each chip, their closed-loop sensors, and organ-organ interconnections. Our Missing Organ MicroFormulator concept spawned an award-winning 96-channel MicroFormulator, which served as the foundation for CN Bio Innovations’ recently introduced PhysioMimixTM pharmacokinetic (PK) system that supports PK studies of oncological drugs. As our group develops its fourth generation of rotary microfluidic pumps and valves to enable our construction and Ross King’s coding of the machine-learning algorithms for the 1000-channel Genesis Self-Driving Chemostat for yeast systems biology, we realize that this hardware can be readily adapted to perfuse and control a dozen of Steve George’s and Scott Simon’s bone marrow and skin chips in an in vitro infection model, maintain and analyze multiple, coupled organ chips for six months or longer, support remote studies of select agents in a BSL-3 or BSL-4 facility, apply circadian rhythms to thousands of wells in dozens of well plates or hundreds of zebrafish or perfused organ chips, and accelerate and optimize the microbial production of antibodies, industrial feed stocks, food protein, and sequestered carbon dioxide. Is this over-engineering or the future of artificial intelligence in biology?

18:00

John T McDevittKeynote Presentation

Development and Deployment of ‘Smart Diagnostics’: Next Generation Point of Care Sensors with Capacity to Learn
John T McDevitt, Professor, Division of Biomaterials, New York University College of Dentistry Bioengineering Institute, United States of America

While COVID-19 has yielded devastating consequences over the past few years, the global pandemic also has opened the door for acceleration of development of core diagnostic capabilities that have the potential to lead to lasting impact for our society. With this vantage point in mind, in the recent past the McDevitt laboratory has launched a series of efforts that target the development and deployment of ‘smart diagnostics’ that serve as distributed point of care sensor nodes with capacity to learn. These mini-sensor ensembles with embedded artificial intelligence integrate programmable chip-based diagnostic systems capable of multiplexed measurements alongside clinical decision support tools that utilize strategically chosen nonclinical data elements that elicit signatures that can be used to capture diseases before they spiral out of control. As such, these efforts link for the first-time the following five key disciplines: i) lab-on-a-chip technologies, ii) in vitro diagnostics, iii) -omics research, iv) artificial intelligence, and v) digital healthcare delivery systems.

Importantly, the combination of point-of-care medical microdevices and machine learning has the potential transform the practice of medicine. In this area, scalable lab-on-a-chip devices have many advantages over standard laboratory methods including portability, faster analysis, reduced cost, lower power consumption, and higher levels of integration and automation. Despite significant advances in medical microdevice technologies over the years, several remaining obstacles are preventing clinical implementation and market penetration of these novel medical microdevices. Similarly, while machine learning has seen explosive growth in recent years and promises to shift the practice of medicine toward data-intensive and evidence-based decision making, its uptake has been hindered due to the lack of integration between clinical measurements and disease determinations.

In this talk, our recent advances in ‘smart diagnostics’ will be highlighted. These smart diagnostics include single-use microfluidic cartridges that serve as fully integrated, self-contained devices that contain aqueous buffers suitable for automated completion of all assay steps within nontraditional healthcare settings. Further, a portable analyzer instrument is fashioned to integrate fluid delivery, optical detection, image analysis, and user interface, representing a universal system for acquiring, processing, and managing clinical data while overcoming many of the challenges facing the widespread clinical adoption of lab-on-a-chip technologies. Intimate linkages between these medical microdevices and cloud connected databases allows for early disease detection algorithms to be used to impact clinical progress.

18:30

Networking Reception with Beer, Wine and a Light Dinner in the Exhibit Hall -- Meet Colleagues and Network with Sponsors and Exhibitors

20:00

Close of Day 1 of the Conference

Tuesday, 14 December 2021

08:00

Conference Registration and Continental Breakfast Served in the Exhibit Hall

08:30

Please Refer to the Lab-on-a-Chip and Microfluidics Agenda for Programming for the Morning Session of December 14, 2021

12:30

Buffet Lunch and Networking in the Exhibit Hall with Exhibitors and Conference Sponsors

13:00

Beyond Wax Printing: Fabrication of Paper-Based Microfluidic Devices Using Commercially Available Printers
Andres Martinez, Professor, California Polytechnic State University, United States of America

Paper-based microfluidic devices, also known as microPADs, are a promising platform for the development of point-of-care diagnostic devices. Like conventional microfluidic devices, microPADs can manipulate and analyze small volumes of fluids. Paper-based devices are also portable, inexpensive to fabricate, simple to operate, and can complete an assay without relying on electrical power or supporting equipment. To fabricate paper-based devices, hydrophobic inks are patterned onto sheets of paper to create hydrophobic barriers that define hydrophilic channels and test zones. One of the simplest and most popular methods of fabricating microPADs is known as wax printing, where a solid ink printer is used to pattern wax on paper. Unfortunately, solid ink printers were discontinued in 2016 and are no longer available commercially. This talk will describe our efforts to develop alternative methods of fabricating paper-based microfluidic devices using commercially available printers that retain the conveniences of wax printing.


15-Minute Oral Presentations of Selected Posters in the POCD Track -- Venue: Coronado Ballroom C

13:15

Ultra-sensitive VFA-based Rapid Detection of Interleukin 6 for Inflammatory Disease
Rongwei Lei, Predoctoral student, University of Houston, United States of America

Increased IL-6 has been reported in chronic diseases such as Rheumatoid Arthritis, cytokine release syndrome (CRS) and sepsis. This work seeks to provide healthcare with a real-time vertical flow assay monitor for tracking IL-6 levels, for early diagnosis and potential IL-6 blockade therapy. After a thorough screening of sizes of gold-NP, membranes, and buffers, the detection of recombinant IL-6 in spiked buffer was found to have a limit of detection of 10 pg/ml and a reportable range of 10-10,000 pg/ml within 15 min assay time. The detection of IL-6 in spiked pooled healthy serum has a LoD of 3.2 pg/ml and a reportable range of 10-10,000 pg/ml. VFA cartridge stability was assessed by comparing one-day, two-week, four-week and six-week storage at room temperature. The standard curves were built under each condition to demonstrate the impact of storage on cartridge stability. Inter-operator CV was assessed by building three standard curves among three researchers and the intra-operator CV was assessed by building three standard curves by one researcher, demonstrating 14.3% and 15.2% CV, respectively. This ultra-sensitive assay can be used for monitoring IL-6 levels for treatment adjustments and assessment of the need for ICU admission or to prognosticate.


Session Title: Point-of-Care Diagnostics: Technologies and Applications


Venue: Marriott Coronado Island Ballroom C

13:30

Joseph WangKeynote Presentation

Wearable Electrochemical Sensors for Healthcare, Nutrition, and Wellness
Joseph Wang, Distinguished Professor, SAIC Endowed Chair, University of California-San Diego, United States of America

Wearable sensors have received major recent attention owing to their considerable promise for monitoring the wearer’s health and wellness. These devices have the potential to continuously and non-invasively collect vital health information from a person’s body and provide this information in a timely fashion. This presentation will discuss our recent efforts toward filling the gaps toward obtaining biochemical information, beyond that given by common wrist-watch mobility trackers. Such real-time molecular information is achieved using advanced wearable electrochemical biosensors integrated directly on the epidermis or within the mouth. The fabrication and applications of such wearable electrochemical sensors will be described, along with their current status and future prospects and challenges.

14:00

Holger SchmidtKeynote Presentation

Advanced Optofluidic Devices for Point-of-Care Molecular Diagnostics
Holger Schmidt, Narinder Kapany Professor of Electrical Engineering, University of California-Santa Cruz, United States of America

Ultra-sensitive and compact instruments with low complexity are highly desirable for real-time point-of-care disease detection. I will describe liquid-core waveguide optofluidic devices for both fluorescence and label-free detection of SARS-CoV-2 from clinical nasal swab samples with single molecule sensitivity. Multiplex detection of single viral antigens is demonstrated along with dual detection of viral DNA and antigen as well as label-free nanopore sensing of single RNAs with 2,000x enhanced detection rate. I will also discuss strategies for implementing optimized particle recognition algorithms and real-time analysis of weak fluorescence signals from single molecules.

14:30

Counting Molecules, Dodging Blood Cells: Continuous, Real-Time Molecular Measurements Directly in the Living Body
Kevin Plaxco, Professor, University of California-Santa Barbara, United States of America

The availability of technologies capable of tracking the levels of drugs, metabolites, and biomarkers in real time in the living body would revolutionize our understanding of health and our ability to detect and treat disease. Imagine, for example, a dosing regimen that, rather than relying on your watch (“take two pills twice a day”), is instead guided by second-to-second measurements of plasma drug levels wirelessly communicated to your smartphone. Such a technology would likewise provide researchers and clinicians an unprecedented window into neurology and physiology, and could even support ultra-high-precision personalized medicine in which drug dosing is optimized minute-by-minute using closed-loop feedback control. Towards this goal, we have developed a biomimetic, electrochemical sensing platform that supports the high frequency, real-time measurement of specific molecules (irrespective of their chemical reactivity) in situ in the blood and tissues of awake, freely moving subjects.

15:00

Developing Diagnostic Technologies for the Home-based Healthcare Paradigm
Paul Yager, Professor, Department of Bioengineering, University of Washington and CSO, UbiDX, Inc., United States of America

For decades, testing of human samples for acute and chronic diseases has been in centralized laboratories where tests were carried out by trained technicians or by large robotic instruments capable of batch processing hundreds of tests.  Since 2008 the Yager lab at UW has, under support of NIH, NSF, DARPA, the UW Army and DTRA, focused on low-cost point-of-care biomedical diagnostics using two-dimensional porous networks (“paper microfluidics") for ultra-low-cost point-of-care pathogen identification.  Novel approaches to both on-device nucleic acid amplification and sensitive protein detection were developed and reduced to practice.  The COVID-19 pandemic, and the restriction of large portions of the world’s population to their homes has opened up new markets for many types of rapid home testing.  It has also exposed people to the long-term possibilities for medical testing at home.  Like many of our colleagues, for the last year (under support of WRF and the Emergent Ventures Rapid Grant), our lab has pivoted to address the pandemic by focusing on a respiratory pathogen panel that incudes SARS-CoV-2. The goal is a rapid semiquantitative validated highly-sensitive multiplexed nucleic acid test using isothermal amplification that can be stored for months at room temperature, but deliver results to an untrained home user (and perhaps also to public health authorities) from a nasal swab within 30 minutes.  We will show our latest results.  

The ability to detect and quantify a wide range of pathogens within an hour of sample acquisition opens up a range of health monitoring opportunities.  By coupling low-cost disposables with an optical reader, it is possible to have a home-based system to detect a wide of range of conditions beyond acute infections, allowing putting an integrated system for health maintenance in the home (or any POC setting) at low cost.  This approach is being commercialized by a new company, UbiDX.

15:30

Danilo TagleKeynote Presentation

Developing Novel Point of Care Diagnostics to Detect SARS-CoV-2
Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

The National Institutes of Health (NIH) launched the Rapid Acceleration of Diagnostics (RADx) initiative to meet the needs for COVID-19 diagnostic and surveillance testing, and also to speed its innovation in the development, commercialization, and implementation of new technologies and approaches. The RADx Radical (RADx-rad) initiative is one component of the RADx program which focuses on the development of new, or non-traditional applications of existing approaches, to enhance their usability, accessibility, and/or accuracy for the detection of SARS-CoV-2.  This presentation will elaborate on two RADx rad programs led by the National Center for Advancing Translational Sciences on 1) pivoting technologies being developed for the isolation of exosomes towards screening and detection for SARS-CoV-2 viral infection due to the similar physical and chemical properties between exosomes and SARS-CoV-2 virus; and 2) developing novel biosensing capabilities using electronic nose technologies to detect unique signatures of volatile organic compounds (VOCs) of those with COVID-19 (Screening for COVID-19 by Electronic-Nose Technology (SCENT)).

16:00

Digital Resolution Liquid Biopsy at the Point of Care
Brian Cunningham, Professor and Intel Alumni Endowed Chair, University of Illinois at Urbana-Champaign, United States of America

As clinicians seek improved methods for tailoring medical treatment to the specific needs of individual patients, research is revealing that an important reservoir of information relevant to gene expression, mutation burden, immune response, and pathogen exposure is available in the profile of biomolecules present in bodily fluids.  Because samples can be obtained non-invasively, so-called “liquid biopsies” enable testing for disease onset, measuring the effects of therapy, and monitoring for disease recurrence after treatment. As liquid biopsy approaches become more routine, they also offer the promise for monitoring metrics for health/wellness, quantifying the effects of nutritional regimens, and determining the effects of exposure to a variety of environments.  Practical realization of this goal is challenging due to the extremely low concentration of relevant biomolecules within complex fluids, and the desire to accurately quantify concentrations that can vary over several orders of magnitude.  For widespread adoption, it is important to develop simple assay methods with inexpensive instruments that can potentially be used at the point of care. This talk will describe ultrasensitive and highly selective biomolecular detection approaches developed by our team that achieve digital resolution detection of nucleic acid and protein biomarkers with rapid, single-step, room temperature workflows that do not require enzymatic amplification.  Utilizing photonic metamaterials in combination with novel biochemistry methods for biomarker recognition, we envision liquid biopsy approaches that can provide quantitative assessments for multiplexed targets in point of care settings.

16:30

Applied Microarrays, A SCHOTT Minifab CompanyMolecular Diagnostic Devices on Polymer, Glass, and Silicon: From Prototyping to Manufacture
Tamma Kaysser-Kranich, VP Chief Technology Officer, Applied Microarrays, A SCHOTT Minifab Company

Molecular diagnostic device design incorporates key factor selections of detection method, substrate type, format, active surface chemistry, biological detector type, cartridge format and requirements, as well as several others.  Each of these factors is key to a successful product design, and an integrated approach to the design early on can lead to fewer product design changes and more rapid product launch along the developmental project pathway.

17:00

microfluidic ChipShop GmbHOpen Analytical Platform – One For All, All For One
Claudia Gärtner, CEO, microfluidic ChipShop GmbH

An open analytical platform will be presented that not only combines the ability to carry out various kinds of immunological, molecular or clinical chemistry tests, can hold for different sample types and can be used with a variety of detection technologies but in particular serves as open platform for users to integrate their own assays. A pathway for individual assay and fluidic development will be shown keeping with standard footprints and a common instrument allowing parties to utilize this platform as starting point for new assay developments.

17:30

Next Generation Point-of-Care Quantitative Molecular Tests For Blood-borne Viral Pathogens
Jonathan D Posner, Professor of Mechanical Engineering & Chemical Engineering, University of Washington, United States of America

Simple, self-administered molecular tests for blood-borne viruses remains a significant challenge due to the numerous sample preparation challenges, low detection limits required for viral pathogens, and difficulty in rapid quantification. Here we describe a paper membrane based NAAT with integrated sample preparation and amplification using recombinase polymerase amplification.  We quantify RNA using amplification nucleation site counting on paper membranes, a novel, rapid, and inexpensive analog to digital droplet isothermal amplification.  We discuss the challenges of detecting RNA targets in blood and alternative sample preparation strategies that can be integrated onto paper substrates. We demonstrate our POC viral diagnostic on HIV-1 virus and hepatitis C in whole blood.

18:00

BIODOT, Inc.Opportunities and Challenges of Low Volume (nL) and Ultra-low Volume (pL) Dispensing in Development and Production of POC Devices
Chris Fronczek, Director of Applications, BIODOT, Inc.

As assay reagent volumes are being reduced while production throughput is increasing, low volume dispensing continues to be a critical piece in the POC industry, at both the R&D and manufacturing level. Multiple reagents dispensed in pL or nL volumes onto hundreds of parts can require thousands of precise movements. In this talk I will discuss realistic considerations for low and ultra-low volume dispensing with highlights for recent case studies and manufacturing applications.

18:30

Networking Reception with Beer and Wine: Network with Colleagues and Engage with Exhibitors and Conference Sponsors

19:30

Close of Conference Day 2 Main Conference Programming

Wednesday, 15 December 2021

08:00

Please Refer to the Organoids and Organs-on-Chips Agenda for Programming Details on Wednesday, December 15, 2021


Add to Calendar ▼2021-12-13 00:00:002021-12-15 00:00:00Europe/LondonPoint-of-Care Diagnostics and Biosensors 2021Point-of-Care Diagnostics and Biosensors 2021 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com